This is what a buyer checks before they shortlist a pharma, medical and life sciences supplier.
What does a partner check before licensing or sourcing biotech material?
They check the development stage and the data supporting it, the intellectual property position, and whether manufacturing can scale. Biotech partnering is an evidence and rights question, so stage-appropriate disclosure matters more than breadth of claim.
A business development team is assessing whether a programme is real enough and protected enough to justify a partnering conversation.
Reviewed 4 August 2026 · Written for biotechnology companys selling to business buyers
What does a partner check before licensing or sourcing biotech material?
What a buyer needs to identify the product
These are the fields a buyer scans before deciding whether you are worth contacting. Missing one of them usually ends the visit without an email.
- 1
Technology platform and application
What the technology does and where it applies.
- 2
Development stage
Research, preclinical, clinical or commercial changes everything.
- 3
Intellectual property position
Patents granted, pending and their territories.
- 4
Manufacturing capability and scale
Whether the product can be made at commercial scale.
- 5
Regulatory pathway
The route and stage in each target market.
- 6
Quality systems in place
Determines readiness for regulated work.
- 7
Partnering model sought
Licensing, supply, co-development or acquisition.
The documents buyers ask for
Not all of them belong on a public page. Naming the ones you can issue is what separates a supplier who can be audited from one who cannot.
| Document | What it proves | Where it belongs |
|---|---|---|
| Intellectual property summaryAsked at: partnering discussion — the core asset | Patent families, status and territories | Name it, share on request |
| Development stage data packageAsked at: due diligence | The evidence supporting the current stage | Name it, share on request |
| Quality certificationAsked at: partner assessment | Quality systems appropriate to the development stage | Publish it |
| Manufacturing capability statementAsked at: commercial assessment | Scale achieved and scale achievable | Name it, share on request |
| Regulatory correspondence summaryAsked at: due diligence | Interactions and agreed pathway with authorities | Name it, share on request |
| Publication and peer review recordAsked at: credibility assessment | Independently reviewed evidence for the platform | Publish it |
| Material transfer and confidentiality termsAsked at: before any exchange | How material and data are shared before a deal | Publish it |
Where biotechnology sites lose the enquiry
Each of these is common, cheap to fix, and costs an enquiry that never arrives — so nobody ever reports it.
Development stage described ambiguously
Partners assess risk by stage. Language that blurs preclinical and clinical work is read as either inexperience or concealment, and both end the conversation.
Intellectual property position not summarised
In biotech the rights are the asset. A programme whose protection cannot be assessed cannot be valued.
Claims made beyond the data
Sophisticated partners check against the literature. Overstating what the evidence supports damages credibility beyond recovery.
What the enquiry form should ask
A form that collects these can be answered properly the first time. A form that collects a name and a message cannot.
Enquiry form — biotechnology
Enough to reply usefully, short enough that a buyer finishes it.
- Technology and application of interest
- Determines the fit.
- Partnering model sought
- Licensing, supply or co-development.
- Development stage required
- Partners have stage preferences.
- Territory and rights of interest
- Defines the deal shape.
- Technical due diligence needs
- What evidence will be required.
- Timeline and decision process
- Partnering timelines are long.
Questions suppliers ask
How much should a biotech company publish publicly?
Enough for a partner to determine fit and credibility: the platform, the application, the development stage, the publication record and the partnering model sought. The data package belongs behind confidentiality, but a site that says nothing specific cannot start a conversation either.
How should development stage be described?
Precisely and conservatively, using the standard terminology for the field. Partners assess risk by stage, and precision is read as competence. Ambiguity intended to make a programme look more advanced is detected quickly and remembered.
What role does the publication record play?
It is often the strongest public credibility signal available, because it is independently reviewed. Listing peer-reviewed publications lets a partner assess the science before contact, which is exactly what they want to do first.
Documents and standards named here are the ones buyers in this industry commonly ask for; requirements vary by market, customer and contract, so treat this as a starting checklist rather than a compliance list. Clearer pages can help discovery and evaluation. They do not guarantee rankings, AI citations, enquiries or revenue.
Illustrative
An enquiry from this search looks like: Partnering model sought · Timeline and decision process · Technology and application of interest · Development stage required
Related buyer questions
- Pharma and ingredientsWhat does a formulator check before qualifying a new API or excipient supplier?
- Medical devicesWhat does a distributor check before taking on a medical device?
- Surgical instrumentsWhat does a hospital buyer check before approving surgical instruments?
- Waste managementWhat does a business check before appointing a waste contractor?